Medifast DEF 14A: Executive Equity Awards Detailed
Ticker: MED · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 910329
Sentiment: neutral
Topics: executive-compensation, equity-awards, DEF-14A
TL;DR
Medifast DEF 14A out: exec equity awards for 2024 detailed, vesting & prior valuations shown.
AI Summary
Medifast Inc. filed a DEF 14A on April 29, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation, including equity awards granted and outstanding. Key figures relate to the fair value of equity awards for the fiscal year 2024, with specific data points on vesting dates and prior year valuations.
Why It Matters
This filing provides transparency into how Medifast Inc. compensates its top executives through equity awards, which can impact shareholder value and company performance.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing detailing executive compensation and does not present immediate financial risks.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for executive compensation details.)
- 20250429 — Filing Date (Date the DEF 14A was submitted to the SEC.)
Key Players & Entities
- MEDIFAST INC (company) — Filer
- 0000910329 (company) — Central Index Key
- 11445 CRONHILL DRIVE (address) — Business Address
- OWINGS MILLS (location) — Business City
- MD (location) — Business State
- 21117 (zip_code) — Business Zip
- HEALTHRITE INC (company) — Former Company Name
FAQ
What is the total fair value of equity awards granted to named executive officers in fiscal year 2024?
The filing indicates data points related to the fair value of equity awards granted in covered years, but specific total dollar amounts for 2024 are not directly extracted from the provided text snippet.
When were the equity awards granted in fiscal year 2024 scheduled to vest?
The filing includes data points for 'VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember' for fiscal year 2024, indicating vesting information is detailed.
What was the fair value of outstanding and unvested equity awards as of the end of fiscal year 2024?
The filing references 'YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember' for fiscal year 2024, suggesting this information is present.
Were there any changes in the fair value of equity awards granted in prior years that were outstanding and unvested during fiscal year 2024?
Yes, the filing includes 'ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember' for fiscal year 2024, indicating changes in prior year awards are tracked.
Does the filing mention any dividends or other earnings paid on equity awards not otherwise reflected in total compensation for fiscal year 2024?
Yes, the filing includes 'DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember' for fiscal year 2024, suggesting this information is addressed.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding MEDIFAST INC (MED).